Cyclacel Pharmaceuticals Inc (CYCC)
1.75
-0.03
(-1.69%)
USD |
NASDAQ |
Apr 22, 16:00
1.76
+0.01
(+0.57%)
After-Hours: 20:00
Cyclacel Pharmaceuticals Cash from Financing (Quarterly): 0.999M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| February 29, 2024 | 579.00M |
| December 31, 2023 | 0.999M |
| September 30, 2023 | -0.05M |
| June 30, 2023 | -0.051M |
| March 31, 2023 | -0.05M |
| December 31, 2022 | 0.042M |
| September 30, 2022 | 1.532M |
| June 30, 2022 | 1.474M |
| March 31, 2022 | -0.05M |
| December 31, 2021 | 0.887M |
| September 30, 2021 | 2.904M |
| June 30, 2021 | -0.051M |
| March 31, 2021 | 18.00M |
| December 31, 2020 | 11.35M |
| September 30, 2020 | -0.05M |
| June 30, 2020 | 18.26M |
| March 31, 2020 | -0.05M |
| December 31, 2019 | -0.05M |
| September 30, 2019 | -0.057M |
| June 30, 2019 | -0.101M |
| March 31, 2019 | 4.056M |
| December 31, 2018 | 0.58M |
| September 30, 2018 | -0.05M |
| June 30, 2018 | -0.051M |
| March 31, 2018 | -0.05M |
| Date | Value |
|---|---|
| December 31, 2017 | 0.148M |
| September 30, 2017 | 13.64M |
| June 30, 2017 | 0.926M |
| March 31, 2017 | 0.036M |
| December 31, 2016 | 1.503M |
| September 30, 2016 | 5.037M |
| June 30, 2016 | 0.104M |
| March 31, 2016 | -0.05M |
| December 31, 2015 | 0.434M |
| September 30, 2015 | 0.17M |
| June 30, 2015 | -0.127M |
| March 31, 2015 | 10.38M |
| December 31, 2014 | 1.385M |
| September 30, 2014 | -0.05M |
| June 30, 2014 | 9.239M |
| March 31, 2014 | 1.626M |
| December 31, 2013 | 1.951M |
| September 30, 2013 | 3.078M |
| June 30, 2013 | 19.02M |
| March 31, 2013 | 3.285M |
| December 31, 2012 | 1.041M |
| September 30, 2012 | 0.014M |
| June 30, 2012 | -0.025M |
| March 31, 2012 | 2.945M |
| December 31, 2011 | 0.009M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.101M
Minimum
Jun 2019
579.00M
Maximum
Feb 2024
31.69M
Average
-0.004M
Median
Cash from Financing (Quarterly) Benchmarks
| Corvus Pharmaceuticals Inc | 0.00 |
| Oragenics Inc | -0.1806M |
| Relmada Therapeutics Inc | -0.0985M |
| Alpine Immune Sciences Inc | 156.61M |
| MAIA Biotechnology Inc | 5.025M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.91M |
| Free Cash Flow | -16.12M |
| Free Cash Flow Per Share (Quarterly) | -4.405 |
| Free Cash Flow to Equity (Quarterly) | -3.91M |
| Free Cash Flow to Firm (Quarterly) | -3.91M |
| Free Cash Flow Yield | 4.14M% |